Movizolo Tab subject to drug shortage prevention program

By Lee, Tak-Sun | translator Alice Kang

24.12.27 05:03:48

가나다라 0

Only 2 items other than YooYoung Pharm’s Rucalo remain as same ingredient reimbursed formulations

Chronic supply and demand shortage arises due to rising costs...Pharmbio’s Movizolo Tab is the only drug that applied for designation as a drug shortage prevention drug

Pharmbio Korea’s Movizolo Tab, a prucalopride succinate-based drug used to treat chronic constipation, will be designated as a drug shortage prevention drug, resulting in an increase in drug price.

Until now, prucalopride-based drugs have faced supply challenges due to low drug prices.

According to industry sources on January 26, Pharmbio Korea’s Movizolo Tab will be designated as a drug shortage prevention drug as of January next year.

The first formulation among the same ingredient drugs to be commercialized was YooYoung Pharm’s Rucalo Tab. The original drug is Korea Janssen's Resolor Tab, however, the drug has been supplied without reimbursement as of now.
<

Lee, Tak-Sun(hooggasi2@dailypharm.com)

If you want to see the full article, please JOIN US (click)